Proinflammatory cytokines in the saliva of patients with active and nonactive Crohn's disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 5, 2012, Pages 200-208

  Szczeklik, Katarzyna ^a   Owczarek, Danuta ^a   Pytko Polończyk, Jolanta ^a   Kȩsek, Barbara ^a   Mach, Tomasz H ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Crohn's disease; Interleukin 1 ; Interleukin 6; Oral cavity; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MOUTH EXAMINATION; PREVALENCE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SALIVA ANALYSIS; SALIVA LEVEL;

EID: 84863434646     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1256     Document Type: Article

References (33)

1. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010: 4: 7-27.
2. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohn's Colitis. 2010; 4: 28-62.
3. Owczarek D, Cibor D, Szczepanek M, Mach T. Biological therapy of inflammatory bowel disease. Pol Arch Med Wew. 2009; 119: 84-89.
4. Dudeney TP. Crohn's disease of the mouth. Proc R Soc Med. 1969; 62: 1237.
5. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976; 55: 401-412.
6. Cosnes A, Dupuy A, Revuz J, et al. Long-term evolution of oral localisation of Crohn's disease. Gastroenterology.1998; 114: A956.
7. Dupuy A, Cosnes J, Revuz J. Oral Crohn's disease: clinical characteristics and long-term follow-up of 9 cases. Arch Dermatol. 1999; 135: 439-442. (Pubitemid 29172096)
8. Pittock S, Drumm B, Fleming P, et al. The oral cavity in Crohn's disease. J Pediatr. 2001; 138: 767-771. (Pubitemid 32417685)
9. Mach T, Szczeklik K, Garlicka M, Owczarek D. [Oral ulceration in patient with active Crohn's disease]. Przegl Gastroenterol. 2007; 2: 210-213. Polish.
10. Michailidou E, Arvanitidou S, Lombardi T, et al. Oral lesions leading to the diagnosis of Crohn disease: report on 5 patients. Quintessence Int. 2009; 40: 581-588.
11. Halme L, Meurman JH, Laine P, et al. Oral findings in patients with active or inactive Crohn's disease. Oral Surg Oral Med Oral Pathol. 1993; 76: 175-181. (Pubitemid 23262575)
12. Rowland M, Fleming P, Bourke B. Looking in the mouth for Crohn's disease. Inflamm Bowel Dis. 2010; 16: 332-337.
13. Scully C, Cochran KM, Russell RI, et al. Crohn's disease of the mouth: an indicator of intestinal involvement. Gut. 1982; 23: 198-201. (Pubitemid 12183730)
14. Stricker T, Braegger CP. Images in clinical medicine. Oral manifestations of Crohn's disease. N Engl J Med. 2000; 342: 1644. (Pubitemid 30341534)
15. Harty S, Fleming P, Rowland M, et al. A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol. 2005; 3: 886-891. (Pubitemid 41219291)
16. Logan RM. Links between oral and gastrointestinal health. Curr Opin Support Palliat Care. 2010; 4: 31-35.
17. Lawrence HP. Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J Canad Dental Assoc. 2002; 68: 170-174.
18. Streckfus CF, Bigler LR. Saliva as a diagnostic fluid. Oral Dis. 2002; 8: 69-76. (Pubitemid 34298345)
19. Rhodus NL, Cheng B, Myers S, et al. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol. 2005; 114: 278-283. (Pubitemid 40267669)
20. Rhodus NL, Cheng B, Bowles W, et al. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis. 2006; 12: 112-116.
21. Tobón-Arroyave SI, Jaramillo-González PE, Isaza-Guzmán DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008; 53: 346-352.
22. Zhang Y, Lin M, Zhang S, et al. NFκB-dependent cytokines in saliva and serum from patients with oral lichen planus: A study in an ethnic Chinese population. Cytokine. 2008; 41: 144-149.
23. Teles RP, Likhari V, Socransky SS, Haffajee AD. Salivary cytokine levels in subjects with chronic peridontitis and in periodontally healthy individuals: a cross-sectional study. J Periodontal Res. 2009; 44: 411-417.
24. Nielsen A, Nielsen NJ, Schmedes A, et al. Saliva Interleukin-6 in patients with inflammatory bowel disease. Scand J Gastroenterol. 2005; 40: 1444-1448. (Pubitemid 43028206)
25. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444.
26. Zervou F, Gikas A, Merikas E, et al. Oral manifestations of patients with inflammatory bowel disease. Ann Gastroenterol. 2004; 17: 395-401. (Pubitemid 43090236)
27. Rhodus NL, Ho V, Miller CS, et al. NF-kB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev. 2005: 29: 42-45. (Pubitemid 40283497)
28. Razaie A, Ghorbani F, Eshgtork A, Zamani MJ et al. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta 1 in relation to disease activity in Crohn's disease patients. Ann N Y Acad Sci. 2006; 1091: 110-122. (Pubitemid 47092230)
29. Jahanshahi G, Motavasel V, Rezaie A, et al. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci. 2004; 49: 1752-1757. (Pubitemid 40228532)
30. Stein JM, Lammert F, Zimmer V, et al. Clinical periodontal and microbiologic parameters in patients with Crohn's disease with consideration of the CARD15 genotype. J Periodontol. 2010; 81: 535-545.
31. Brailo V, Vucićević-Boras V, Cekić-Arambasin A, et al. The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia. Oral Oncol. 2006; 42: 370-373.
32. Brailo V, Vucicevic-Bores V, Lukac J, et al. Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Med Oral Patol Oral Cir Bucal. 2012; 17: e10-e15.
33. Rhodus NL, Cheng B, Myers S, et al. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005; 44: 77-82. (Pubitemid 41397172)